Safety of trovafloxacin in treatment of lower respiratory tract infections

@article{Williams2005SafetyOT,
  title={Safety of trovafloxacin in treatment of lower respiratory tract infections},
  author={D. Williams and S. Hopkins},
  journal={European Journal of Clinical Microbiology and Infectious Diseases},
  year={2005},
  volume={17},
  pages={454-458}
}
  • D. Williams, S. Hopkins
  • Published 2005
  • Medicine
  • European Journal of Clinical Microbiology and Infectious Diseases
Safety and toleration of oral trovafloxacin has been assessed in Phase III trials in patients with acute lower respiratory tract infections. Patients were treated orally with either trovafloxacin 100 or 200 mg (n=881) or a comparator (500 or 1000 mg amoxicillin, or 625 mg amoxicillin/clavulanic acid;n=593). Adverse events were recorded in 112 (12.7%) trovafloxacin- and 74 (12.5%) comparator-treated patients. Frequency of effects on the autonomic nervous, musculoskeletal, respiratory, special… Expand
Levofloxacin for the treatment of pyelonephritis
TLDR
Levofloxacin is no longer a suitable option for first-line empirical treatment of pyelonephritis in areas where resistance rates are high (> 10%) when pyel onephritis is hospital-acquired and its prescription should be performed in compliance with antimicrobial guidelines. Expand
Fluoroquinolones in Pediatrics
TLDR
The new FQ have shown excellent in- vitro activity against penicillin-resistant Streptococcus pneumoniae suggesting that these agents may be an attractive alternative for the treatment of conditions that involve these problematic strains. Expand
Adverse drug reactions: implications for the development of fluoroquinolones.
  • P. Ball
  • Medicine
  • The Journal of antimicrobial chemotherapy
  • 2003
TLDR
Quinolone antibacterials, originally derived from anti-malarial compounds, have been developed through side-chain and nuclear manipulation, notably by piperazine and other mono- or bi-cyclic substitutions at the 7 position and fluorination at various sites (giving increased anti-Gram-positive activity). Expand
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium
TLDR
First-line treatment of CAP patients with moxifloxacin followed by co-amoxiclav or hospitalisation if required was more effective and less costly as compared with first- line treatment with co-Amoxiclav, cefuroxime or clarithromycin. Expand
Molecular docking and molecular dynamics studies on the structure-activity relationship of fluoroquinolone for the HERG channel.
TLDR
The results showed that the CH3 group in MX was favorable for the binding to the HerG channel, while Tyr652 and Phe656 were critical for the hydrophobic interaction between fluoroquinolones and the HERG channel. Expand
Role of Metabolism in Drug Toxicity

References

SHOWING 1-10 OF 35 REFERENCES
Treatment of uncomplicated urinary tract infections with temafloxacin.
  • A. Iravani
  • Medicine
  • The American journal of medicine
  • 1991
TLDR
These results demonstrate the clinical efficacy and safety of temafloxacin, given once daily, in a large number of females with acute, uncomplicated urinary tract infection. Expand
Treatment of acute exacerbations of chronic bronchitis: Comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study
TLDR
Although all three treatments produced similar bacteriological efficacy, there was a trend towards higher eradication rates forHaemophilus influenzae among patients (both clinically evaluable and intent-to-treat populations) treated with trovafloxacin 200 mg compared with those treated with amoxicillin. Expand
Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.
TLDR
Although all three treatments produced similar bacteriological efficacy, there was a trend towards higher eradication rates for Haemophilus influenzae among patients (both clinically evaluable and intent-to-treat populations) treated with trovafloxacin 200 mg compared with those treated with amoxicillin. Expand
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
TLDR
Treatment-related adverse events were comparable; the most common were headache, vomiting and dizziness in trovafloxacin patients, and diarrhoea, headache and abdominal pain in amoxicillin patients. Expand
Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis
TLDR
Treatments with once-daily trovafloxacin and amoxicillin/ clavulanic acid were compared in adults with acute exacerbations of chronic obstructive bronchitis to achieve eradication of three pathogens: Streptococcus pneumoniae, chlamydia and tuberculosis. Expand
The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.
  • E. Rizk
  • Medicine
  • The American journal of medicine
  • 1992
TLDR
The results of the U.S. clinical program indicate that lomefloxacin administered orally once daily is effective and well tolerated in a variety of infections of bacterial origin. Expand
Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
TLDR
Although the place of pefloxacin in this new and expanding class of 4-quinolone antibacterial drugs has yet to be defined and it appears to be a well-tolerated and useful drug for the treatment of serious infections in hospitalised patients, further studies are awaited with interest for confirmation of these preliminary results. Expand
Side-effects of quinolones: Comparisons between quinolones and other antibiotics
  • S. Norrby
  • Medicine
  • European Journal of Clinical Microbiology and Infectious Diseases
  • 2005
TLDR
Caution is necessary when this group of drugs, especially pefloxacin, is prescribed to patients who will have intensive exposure to UV light during treatment, and carefully monitored studies should be performed in paediatric patients to assess whether there is a real risk of such adverse reactions. Expand
Safety profile of the quinolones.
  • R. Stahlmann
  • Biology, Medicine
  • The Journal of antimicrobial chemotherapy
  • 1990
TLDR
Overall, fluoroquinolones are well tolerated and the incidences of side effects are similar to those of other antibacterials. Expand
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens
  • J. Pechère, T. Gootz
  • Biology, Medicine
  • European Journal of Clinical Microbiology and Infectious Diseases
  • 2005
TLDR
Data from in vitro susceptibility studies and in vivo animal protection models suggest that the new fluoroquinolone, trovafloxacin, may offer clinical efficacy against respiratory pathogens superior to that of ciprofloxacIn and of ofloxACin, and may find a useful role as empiric therapy in both the community and hospital setting. Expand
...
1
2
3
4
...